Pharmaceutical News

RSS

Oral budesonide suspension offers hope for pediatric patients with EoE

A new formulation of oral budesonide suspension, a steroid-based treatment, is safe and effective in treating pediatric patients with eosinophilic esophagitis (EoE), according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

19 Dec 2014

Canopus BioPharma study confirms efficacy of CB008 drug for Ebola Virus inhibition

Canopus BioPharma Inc. today announces that it has completed crucial research in confirming efficacy of a prescription drug: CB008 for Ebola Virus inhibition.

19 Dec 2014

Lilly, Adocia team up to develop BioChaperone Lispro insulin for treatment of diabetes

Eli Lilly and Company and Adocia today announced a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChaperone Lispro, for treatment in people with type 1 and type 2 diabetes.

19 Dec 2014

SLU investigators find promising candidates for new herpes virus treatments

Saint Louis University research findings published in the December issue of Antimicrobial Agents and Chemotherapy report a family of molecules known as nucleotidyltransferase superfamily (NTS) enzyme inhibitors are promising candidates for new herpes virus treatments.

19 Dec 2014

UTSA, UTHSCSA researchers to jointly develop next-generation breast cancer treatment drugs

Stanton McHardy, associate professor of chemistry and director of the Center for Innovative Drug Discovery in The University of Texas at San Antonio College of Sciences, is partnering on a $1.9 million award to develop next-generation breast cancer treatment drugs.

19 Dec 2014

Ipsen's Somatuline Depot Injection 120 mg receives FDA approval for treatment of GEP-NETs

Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen, today announced that Somatuline Depot (lanreotide) Injection 120 mg (referred to as Somatuline) was approved by the U.S. Food and Drug Administration for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic disease to improve progression-free survival (PFS).

19 Dec 2014

Certain complementary medicines may cause side effects, warns NPS MedicineWise

With new information from Melbourne’s Peter MacCallum Cancer Centre revealing that some complementary medicines can interact with cancer treatment, NPS MedicineWise reminds all Australians that complementary medicines can cause side effects, and interact with other over-the-counter and prescription medicines.

19 Dec 2014

CF patients require close monitoring for resistance to ganciclovir after lung transplantation

A drug called ganciclovir is given to lung transplant patients to protect against a life-threatening virus that is common after transplantation.

18 Dec 2014

Sage Analytics releases new Luminary Profiler for testing cannabis potency

Sage Analytics, the developers of a new generation of equipment for the testing of marijuana potency and moisture content, announced today the release of the new Luminary Profiler, the industry's first product suite capable of delivering highly accurate light-based measurement in a cost-effective, portable unit.

18 Dec 2014

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, and ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the companies have entered into a strategic collaboration for the further clinical development and commercialization of CMX157.

18 Dec 2014

High-dose flu vaccine better than regular flu shot for frail, older adults of long-term care facilities

The high-dose flu vaccine is significantly better than the regular flu shot at boosting the immune response to the flu virus in frail, older residents of long-term care facilities, according to the results of a University of Pittsburgh School of Medicine study.

18 Dec 2014

EC grants orphan drug designation to TxCell's Col-Treg for treatment of autoimmune uveitis

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that the European Commission (EC) has granted orphan drug designation to TxCell's investigational medicinal product Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of autoimmune uveitis.

18 Dec 2014

Diabetes drug can boost efficacy of TB medication without causing drug resistance

A more effective treatment for tuberculosis (TB) could soon be available as scientists have discovered that Metformin (MET), a drug for treating diabetes, can also be used to boost the efficacy of TB medication without inducing drug resistance.

17 Dec 2014

Researchers identify 53 existing drugs that may block Ebola virus from entering human cells

Researchers found 53 existing drugs that may keep the Ebola virus from entering human cells, a key step in the process of infection, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai and the National Institutes of Health, and published today in the Nature Press journal Emerging Microbes and Infections.

17 Dec 2014

Tufts University researchers report that extra vitamin E can protect against pneumonia

Extra vitamin E protected older mice from a bacterial infection that commonly causes pneumonia. Microbiologists and nutrition researchers from Tufts University report that the extra vitamin E helped regulate the mice's immune system.

17 Dec 2014

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its third U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab).

16 Dec 2014

Preclinical study strongly supports NT-113 as potential new treatment for glioblastoma multiforme

NewGen Therapeutics, Inc. today announced the publication of preclinical research strongly supporting NT-113, the company's novel irreversible pan-erbB inhibitor (EGFR, HER2 and HER4), as a potential new treatment for glioblastoma multiforme (GBM), the most common and most aggressive malignant primary brain tumor in adults.

16 Dec 2014

CMC Biologics, OncoSynergy partner to develop novel potential treatment for Ebola

CMC Biologics and OncoSynergy have entered into an agreement for process development and GMP manufacture of OS2966 – a novel potential treatment for Ebola. The investigational drug candidate, designed to inhibit a major cellular adhesion receptor (CD29) that is fundamental for progression of aggressive and resistant cancer tumors, was granted orphan drug designation by the U.S. FDA earlier this year in the treatment of glioblastoma.

16 Dec 2014

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Novogen Limited, Australian/US biotechnology company, today announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma.

16 Dec 2014

CARLINA, Atlangram partner to develop antibiotics for osteoarticular infectious diseases

CARLINA Technologies, a biotechnology company specializing in the development of nanomedicines, today announces the signing of a partnership agreement with Atlangram for the development of innovative pharmaceutical forms of antibiotics for the targeting of osteoarticular infectious diseases.

16 Dec 2014

Pharmaceutical News

Oral budesonide suspension offers hope for pediatric patients with EoE

Canopus BioPharma study confirms efficacy of CB008 drug for Ebola Virus inhibition

Lilly, Adocia team up to develop BioChaperone Lispro insulin for treatment of diabetes

SLU investigators find promising candidates for new herpes virus treatments

UTSA, UTHSCSA researchers to jointly develop next-generation breast cancer treatment drugs

Ipsen's Somatuline Depot Injection 120 mg receives FDA approval for treatment of GEP-NETs

Certain complementary medicines may cause side effects, warns NPS MedicineWise

CF patients require close monitoring for resistance to ganciclovir after lung transplantation

Sage Analytics releases new Luminary Profiler for testing cannabis potency

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

High-dose flu vaccine better than regular flu shot for frail, older adults of long-term care facilities

EC grants orphan drug designation to TxCell's Col-Treg for treatment of autoimmune uveitis

Diabetes drug can boost efficacy of TB medication without causing drug resistance

Researchers identify 53 existing drugs that may block Ebola virus from entering human cells

Tufts University researchers report that extra vitamin E can protect against pneumonia

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Preclinical study strongly supports NT-113 as potential new treatment for glioblastoma multiforme

CMC Biologics, OncoSynergy partner to develop novel potential treatment for Ebola

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

CARLINA, Atlangram partner to develop antibiotics for osteoarticular infectious diseases

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News